Due to the prevalence of EGFR expression in bladder cancer cells, EGFR-target noninvasive therapeutics have been recognized as a viable approach for treatment, and consequently have been widely studied in the past decade. This evidence concerns the gene EGFR and urinary bladder carcinoma.